It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Rational Pharmacotherapy in CardiologyProthrombotic polymorphisms and long-term prognosis of patients with stable ischemic heart disease (Full english text)

Prothrombotic polymorphisms and long-term prognosis of patients with stable ischemic heart disease (Full english text)

A.L. Komarov1, O.O. Shahmatova1*, D.V. Rebrikov2,3, D.Yu. Trophimov2, T.I. Kotkina1, T.A. Ilyushenko1, A.D. Deev4, E.P. Panchenko1

1 Russian Cardiology Research and Production Complex. Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia

2 ”DNA-Technology” Research and Production Company. Varshavskoe shosse 125Ж-6, Moscow, 117587 Russia

3 General Genetics Institute named after N.I. Vavilov. Gubkina ul. 3, Moscow, 119991 Russia

4 State Research Center for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia

Aim. To estimate influence of thrombosis associated genetic factors on cardiovascular complications (CVC) occurrence in patients with stable ischemic heart disease (IHD) on the base of 5-year prospective survey.

Material and methods. A total of 503 patients with the mean age of 59.4 years were enrolled into the study. The follow-up period was 5.4 years. Composite endpoint included the following cases of fatal and nonfatal CVC: death, acute coronary syndrome, ischemic stroke/transient ischemic attack, peripheral arterial thrombosis and revascularization of affected vascular system. We determined prevalence and prognostic value of mutations and polymorphisms in genes that encode blood clotting factors (factor V Leiden G1691A, prothrombin G20210A, ß-fibrinogen 455G> A), platelet GPIIIa receptor (C1565T) and enzymes involved in homocysteine metabolism (methylentetrahydrofolate reductase (C667 T MTHFR) and A1298C, methionine synthase (MTR) A2756G, methionine synthase-reductase (MTRR) A66G and transcobalamin (TCN) C776G).

Results. Overall incidence rate of vascular events made up 31.0%. MTHFR and TCN polymorphisms proved to be significant in regard to cardiovascular risk among all studied genetic indices. Carriage of at least C667 T one MTHFR polymorphic allele increased risk of CVC 1.64 times (95% confidence interval (CI) 1.2-2.3, p=0.003). Homozygous carriage of MTHFR 1298 AА and TCN 776 СС “wild” genotypes increased risk of CVC 1.63 times (95% CI 1.2-2.3, р=0.006) and 1.37 times (95% CI 1.001-1.89, р=0.04), respectively. Such genetic variants as MTHFR C667 T/СТ and 1298 AА impacted prognosis only given concomitant decrease in plasma folate level, which was observed in 56.1% of the patients.

Conclusion. It can be recommended to test the presence of MTHFR C667 T, MTHFR 1298 AА and TCN 776 СС, and to simultaneously assess folate level in IHD patients in order to clarify risk of unfavorable cardiovascular events.

Key words: stable ischemic heart disease, prothrombotic polymorphisms, homocysteine metabolism, folate

Rational Pharmacother. Card. 2011;7(4):409-425


Download free full text (PDF)

© 2007 — 2014 «Rational Pharmacotherapy in Cardiology»
«Stolichnaya Izdatelskaya Kompaniya»

ISSN 1819-6446(Print) ISSN 2225-3653 (Online)